Tranexamic Acid in Anesthetic Management of Surgical Procedures

Area of Science:

• Anesthesiology
• Pharmacology
• Surgical Hemostasis

Background:

• Surgical bleeding is a significant risk, and blood transfusions are costly and carry adverse outcomes.
• Antifibrinolytic agents offer an economical and effective strategy to mitigate surgical hemorrhage.
• Tranexamic acid (TXA) is a key antifibrinolytic agent that inhibits clot breakdown.

Purpose of the Study:

• To review the efficacy of antifibrinolytics, specifically TXA, in reducing surgical blood loss.
• To evaluate the safety profile of TXA concerning embolic events.
• To outline the application of TXA in diverse surgical specialties.

Main Methods:

• Review of extensive research on antifibrinolytic use in surgery.
• Analysis of studies investigating TXA's impact on blood loss and transfusion requirements.
• Examination of data regarding the incidence of vascular occlusive events with TXA use.

Main Results:

• Antifibrinolytics, including TXA, effectively decrease intraoperative blood loss.
• TXA can reduce the requirement for allogeneic blood transfusions in surgical patients.
• Current research demonstrates that TXA does not elevate the risk of embolic or vascular occlusive events.

Conclusions:

• TXA is a safe and effective antifibrinolytic agent for reducing blood loss in surgical settings.
• Consideration of TXA on a case-by-case basis is recommended for Certified Registered Nurse Anesthetists.
• TXA presents a valuable option for minimizing blood loss with minimal adverse effects across various surgical disciplines.